Cita APA

Iwamoto, S., Hazama, S., Kin, H., Takemoto, H., Kobayashi, K., Takahashi, Y., . . . Mishima, H. (2016). P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2). Ann Oncol.

Chicago Style Citation

Iwamoto, S., et al. "P-157 A Phase II Study of XELOX and Cetuximab (Erbitux) As First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer (FLEET2)." Ann Oncol 2016.

Cita MLA

Iwamoto, S., et al. "P-157 A Phase II Study of XELOX and Cetuximab (Erbitux) As First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer (FLEET2)." Ann Oncol 2016.